ZyVersa Therapeutics, Inc. (ZVSA) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for ZVSA including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in ZVSA stock with expert risk management insights.

Risk Assessment Summary

High price volatility

Governance Risk

Overall Risk Score

N/A

Audit Risk

N/A

Board Risk

N/A

Compensation Risk

N/A

Shareholder Rights Risk

N/A

Market Risk

Beta (5Y Monthly)

0.83Moderate

52-Week Change

-86.67%Low

S&P 500 52-Week Change

13.26%Very High

Short Interest Ratio

0.25Low

Short % of Float

7.38%Very High

Volatility (Annualized)

184.67%Very High

Financial Risk

Total Debt

$0.00

Enterprise Value

$585.21K

Profit Margins

0.00%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-25695504.00

Book Value

$-1.45

Risk vs Reward Analysis

Risk Factors

Beta: 0.83

Volatility: 184.67%

Short Interest: 0.25

Potential Rewards

52-Week Change: -86.67%

Earnings Growth: N/A

Profit Margin: 0.00%